Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers

Table 1 Baseline information

Indicators	Control group (n = 30)	Research group (n = 32)	χ2/t	P value
Age (years old)	61.03 ± 6.91	61.44 ± 10.61	0.179	0.859
Gender (male/female)	17/13	19/13	0.047	0.829
Clinical staging (II/III)	18/12	16/16	0.625	0.429
Tumor diameter (cm)	5.68 ± 1.29	5.80 ± 1.50	0.337	0.738
History of alcoholism (with/without)	11/19	8/24	0.992	0.319
History of smoking (with/without)	8/22	7/25	0.194	0.660
Family medical history (yes/no)	5/25	9/23	1.163	0.281

Table 2 Short-term efficacy of two groups of esophageal carcinoma patients, n (%)

Indicators	Control group (n = 30)	Research group (n = 32)	χ2	P value
Complete response	6 (20.00)	7 (21.88)	-	-
Partial response	12 (40.00)	13 (40.63)	-	-
Stable disease	7 (23.33)	8 (25.00)	-	-
Progressive disease	5 (16.67)	4 (12.50)	-	-
Overall response rate	18 (60.00)	20 (62.50)	0.041	0.840
Disease control rate	25 (83.33)	28 (87.50)	0.217	0.642

Table 3 Incidence of drug toxicities in two groups of esophageal carcinoma patients, n (%)

Indicators	Control group (n = 30)	Research group (n = 32)	χ2	P value
Myelosuppression
I-II	13 (43.33)	6 (18.75)	4.403	0.036
III-IV	6 (20.00)	2 (6.25)	2.605	0.107
Gastrointestinal reactions
I-II	15 (50.00)	8 (25.00)	4.147	0.042
III-IV	7 (23.33)	3 (9.38)	2.230	0.135
Radiation esophagitis
I-II	14 (46.67)	13 (40.63)	0.230	0.632
III-IV	7 (23.33)	6 (18.75)	0.196	0.658